In a nutshell The authors determined the factors that affected survival in prostate cancer patients with bone tumors when treated with zoledronic acid (Zometa, INN, Reclast). Some background Hormone therapy is commonly used to treat prostate cancer. It involves targeting the male sex hormones active in prostate cancer, such as...
Read More
In a nutshell The authors analyzed the effect of using hormone therapy and targeted therapy, in combination, to treat bone tumors in prostate cancer patients. Some background Hormone therapy is a common treatment for prostate cancer. It reduces the level of male sex hormones (e.g. testosterone) in the body or prevent them from affecting...
Read More
In a nutshell The authors aimed to assess the effectiveness of traditional Chinese medicine used with conventional breast cancer treatments on breast cancer survival. Some background Traditional Chinese medicine is an alternative therapy that can complement breast cancer treatments. This generally includes various forms of herbal medicine,...
Read More
In a nutshell The authors aimed to determine whether dacarbazine was better as a single or combination therapy when treating malignant melanoma. Some background Dacarbazine (DTIC) has been the most used and effective treatment option in malignant melanoma, however it has a low response rate (reduction in the signs or symptoms of cancer) of...
Read More
In a nutshell The authors evaluated skeletal events to determine whether denosumab (Prolia) reduced the risk of skeletal complications in metastatic castration-resistant prostate cancer. Some background Denosumab is a drug used to treat metastatic castration-resistant prostate cancer (cancer which has spread from the prostate and...
Read More
In a nutshell This phase 3 clinical trial assessed the efficacy and safety of radium-223 dichloride or radium-223 (Xofigo) in patients with prostate cancer that has spread to the bone. Some background Testosterone, the main male sex hormone, promotes the growth of prostate cancer. A treatment option for prostate cancer patients is castration...
Read More
In a nutshell In this phase 3 clinical trial, researchers compared the safety and efficacy of vemurafenib to the standard chemotherapy drug for melanoma, dacarbazine. Some background A genetic defect (mutation) in protein called BRAF is present in approximately 50% of melanomas. BRAF helps cells grow and multiply, so BRAF mutations are responsible...
Read More
In a nutshell This phase 3 clinical trial compared the safety and efficacy of dabrafenib to a standard treatment for melanoma, dacarbazine in patients with metastatic melanoma. Some background BRAF is a protein that helps cells grow and multiply. A genetic defect can cause the BRAF protein to malfunction (BRAF mutation). A BRAF mutation is...
Read More
